ReviewZeitschrift fur Rheumatologie2025
[Digital health applications and axial spondyloarthritis].
Review in Zeitschrift fur Rheumatologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- [First approved rheumatological digital health application for axial spondyloarthritis].Zeitschrift fur Rheumatologie · 2026Trial
- Psychosocial dimensions of pain in axial spondyloarthritis: Construct validity and responsiveness of the multidimensional pain inventory (MPI).Therapeutic advances in musculoskeletal disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Digital health applications (DHA) can provide exercise therapy, behavioral interventions or patient education. These interventions are of high relevance in axial spondyloarthritis (axSpA). Therefore, axSpA represents a potentially promising area of DHA usage; however, no DHA has yet been officially approved for axSpA. Currently, the medical apps Axia and RheCORD Plus are in the DiGA approval track. So far, published study results are only available for Axia and appear promising. In addition to these apps, DHAs such as ViViRA or HelloBetter Chronic Pain are being tested in axSpA, and initial study results also show positive effects in this context. The use of DHAs in axSpA thus shows promising potential, although further research is needed to evaluate long-term effectiveness, cost-effectiveness and user acceptance.
Indexed as
Identifiers
41073530What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.